174 results on '"Evans JF"'
Search Results
2. A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model
- Author
-
Swaney, JS, primary, Chapman, C, additional, Correa, LD, additional, Stebbins, KJ, additional, Bundey, RA, additional, Prodanovich, PC, additional, Fagan, P, additional, Baccei, CS, additional, Santini, AM, additional, Hutchinson, JH, additional, Seiders, TJ, additional, Parr, TA, additional, Prasit, P, additional, Evans, JF, additional, and Lorrain, DS, additional
- Published
- 2010
- Full Text
- View/download PDF
3. Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD.
- Author
-
Zhu J, Bandi V, Qiu S, Figueroa DJ, Evans JF, Barnes N, Guntupalli KK, Jeffery PK, Zhu, Jie, Bandi, Venkata, Qiu, Shengyang, Figueroa, David J, Evans, Jilly F, Barnes, Neil, Guntupalli, Kay K, and Jeffery, Peter K
- Abstract
Background: Cysteinyl leukotriene 1 (CysLT1) receptor expression is known to be increased in the airway mucosa of patients with asthma, especially during exacerbations; however, nothing is known of its expression in COPD.Methods: We applied immunohistochemistry and in situ hybridization to endobronchial biopsies to determine inflammatory cell CysLT1 receptor protein and mRNA expression in the following: (1) 15 nonsmoker control subjects (NSC), (2) 16 smokers with moderate to severe COPD in its stable phase (S-COPD), and (3) 15 smokers with COPD hospitalized for a severe exacerbation (SE-COPD).Results: The total number of bronchial mucosal inflammatory cells (CD45+) and those expressing CysLT1 receptor protein were significantly greater in SE-COPD (CysLT1 receptor protein: median [range] = 139 [31-634]) as compared with S-COPD (32 [6-114]) or NSC (16 [4-66]) (P < .001 for both). CysLT1 receptor gene expression showed similar differences. A greater proportion of CD451 cells expressed CysLT1 receptor protein in SE-COPD (median [range] = 22% [8-81]) compared with S-COPD (10% [4-32]) (P < .03) or NSC (7% [1-19]) (P < .002). In SE-COPD, the relative frequencies of CysLT1 receptor-expressing cells were as follows: tryptase1 mast cells > CD681 monocytes/macrophage > neutrophils > CD201 B lymphocytes = EG21 eosinophils. Moreover, there were positive correlations between the numbers of cells expressing CysLT1 receptor protein and the numbers of CD451 cells (r = 0.78; P < .003) and tryptase1 mast cells (r = 0.62; P < .02).Conclusions: Bronchial mucosal CysLT1 receptor-positive inflammatory cells are present in the bronchial mucosa in COPD in greatest number in those experiencing a severe exacerbation. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
4. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.
- Author
-
Swaney, JS, Chapman, C, Correa, LD, Stebbins, KJ, Bundey, RA, Prodanovich, PC, Fagan, P, Baccei, CS, Santini, AM, Hutchinson, JH, Seiders, TJ, Parr, TA, Prasit, P, Evans, JF, Lorrain, DS, Swaney, J S, Correa, L D, Stebbins, K J, Bundey, R A, and Prodanovich, P C
- Subjects
PULMONARY fibrosis ,BLEOMYCIN ,PHOSPHATIDIC acids ,PHARMACOLOGY ,CHEMOTAXIS ,LABORATORY mice ,INTRACELLULAR calcium - Abstract
Background and Purpose: The aim of this study was to assess the potential of an antagonist selective for the lysophosphatidic acid receptor, LPA(1), in treating lung fibrosis We evaluated the in vitro and in vivo pharmacological properties of the high affinity, selective, oral LPA(1)-antagonist (4'-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (AM966).Experimental Approach: The potency and selectivity of AM966 for LPA(1) receptors was determined in vitro by calcium flux and cell chemotaxis assays using recombinant and native cell cultures. The in vivo efficacy of AM966 to reduce tissue injury, vascular leakage, inflammation and fibrosis was assessed at several time points in the mouse bleomycin model.Key Results: AM966 was a potent antagonist of LPA(1) receptors, with selectivity for this receptor over the other LPA receptors. In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC(50)= 17 nM) from Chinese hamster ovary cells stably expressing human LPA(1) receptors and inhibited LPA-induced chemotaxis (IC(50)= 181 nM) of human IMR-90 lung fibroblasts expressing LPA(1) receptors. AM966 demonstrated a good pharmacokinetic profile following oral dosing in mice. In the mouse, AM966 reduced lung injury, vascular leakage, inflammation and fibrosis at multiple time points following intratracheal bleomycin instillation. AM966 also decreased lactate dehydrogenase activity and tissue inhibitor of metalloproteinase-1, transforming growth factor beta1, hyaluronan and matrix metalloproteinase-7, in bronchoalveolar lavage fluid.Conclusions and Implications: These findings demonstrate that AM966 is a potent, selective, orally bioavailable LPA(1) receptor antagonist that may be beneficial in treating lung injury and fibrosis, as well as other diseases that are characterized by pathological inflammation, oedema and fibrosis. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
5. Report. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.
- Author
-
Brooks, P, Emery, P, Evans, JF, Fenner, H, Hawkey, CJ, Patrono, C, Smolen, J, Breedveld, F, Day, R, Dougados, M, Ehrich, EW, Gijon-Baños, J, Kvien, TK, Van Rijswijk, MH, Warner, T, and Zeidler, H
- Published
- 1999
- Full Text
- View/download PDF
6. Changing the lens: a position paper on the value of qualitative research methodology as a mode of inquiry in the education of the deaf.
- Author
-
Evans JF
- Abstract
A case study of a young deaf child's conversation development is used to explore the relationship between mode of inquiry and findings resulting from the use of qualitative research methodology. Data were collected through participant observation, videotaping, and interviews in the participants' natural settings. The breadth of findings from thematic analysis of descriptive data and discourse analysis of language samples led to the discovery of the child's language competencies in a field where research usually focuses on language deficits. Additionally, data revealed the contextual features that contributed to the child's conversation development. Scope of findings and implications for educators and researchers provide evidence of the value of qualitative methodology as a mode of inquiry in the field of education of the Deaf. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
7. Malignant melanoma and its precursors
- Author
-
Miller Of and Evans Jf
- Subjects
Risk ,Pathology ,medicine.medical_specialty ,Skin Neoplasms ,Biopsy ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Malignancy ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Pigmented Nevus ,Humans ,Child ,Health Education ,Melanoma ,neoplasms ,Skin ,Nevus, Pigmented ,medicine.diagnostic_test ,business.industry ,food and beverages ,General Medicine ,Prognosis ,medicine.disease ,Natural history ,Sunlight ,Identification (biology) ,business ,Rare disease - Abstract
Melanoma is no longer a rare disease. Knowledge of the natural history of pigmented nevi and of the clinical characteristics of melanoma and its precursor and look-alike lesions can help prevent deaths from this treatable malignancy.
- Published
- 1986
8. Signifying pain: constructing and healing the self through writing.
- Author
-
Evans JF
- Published
- 2005
9. Hyperactive mTORC1 in lung mesenchyme induces endothelial cell dysfunction and pulmonary vascular remodeling.
- Author
-
Lin SM, Rue R, Mukhitov AR, Goel A, Basil MC, Obraztsova K, Babu A, Crnkovic S, Ledwell OA, Ferguson LT, Planer JD, Nottingham AN, Vanka KS, Smith CJ, Cantu E 3rd, Kwapiszewska G, Morrisey EE, Evans JF, and Krymskaya VP
- Subjects
- Animals, Humans, Infant, Mice, Endothelial Cells metabolism, Lung metabolism, Mechanistic Target of Rapamycin Complex 1 genetics, Mechanistic Target of Rapamycin Complex 1 metabolism, Mesoderm metabolism, Vascular Remodeling genetics, T-Box Domain Proteins genetics, T-Box Domain Proteins metabolism, In Vitro Techniques, Lymphangioleiomyomatosis genetics, Lymphangioleiomyomatosis metabolism, Tuberous Sclerosis, Tumor Suppressor Proteins genetics, Tumor Suppressor Proteins metabolism, Tuberous Sclerosis Complex 2 Protein genetics, Tuberous Sclerosis Complex 2 Protein metabolism
- Abstract
Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease caused by tuberous sclerosis complex 1/2 (TSC1/2) gene mutations in pulmonary mesenchymal cells, resulting in activation of the mechanistic target of rapamycin complex 1 (mTORC1). A subset of patients with LAM develop pulmonary vascular remodeling and pulmonary hypertension. Little, however, is known regarding how LAM cells communicate with endothelial cells (ECs) to trigger vascular remodeling. In end-stage LAM lung explants, we identified EC dysfunction characterized by increased EC proliferation and migration, defective angiogenesis, and dysmorphic endothelial tube network formation. To model LAM disease, we used an mTORC1 gain-of-function mouse model with a Tsc2 KO (Tsc2KO) specific to lung mesenchyme (Tbx4LME-Cre Tsc2fl/fl), similar to the mesenchyme-specific genetic alterations seen in human disease. As early as 8 weeks of age, ECs from mice exhibited marked transcriptomic changes despite an absence of morphological changes to the distal lung microvasculature. In contrast, 1-year-old Tbx4LME-Cre Tsc2fl/fl mice spontaneously developed pulmonary vascular remodeling with increased medial thickness. Single-cell RNA-Seq of 1-year-old mouse lung cells identified paracrine ligands originating from Tsc2KO mesenchyme, which can signal through receptors in arterial ECs. These ECs had transcriptionally altered genes including those in pathways associated with blood vessel remodeling. The proposed pathophysiologic mesenchymal ligand-EC receptor crosstalk highlights the importance of an altered mesenchymal cell/EC axis in LAM and other hyperactive mTORC1-driven diseases. Since ECs in patients with LAM and in Tbx4LME-Cre Tsc2fl/fl mice did not harbor TSC2 mutations, our study demonstrates that constitutively active mTORC1 lung mesenchymal cells orchestrated dysfunctional EC responses that contributed to pulmonary vascular remodeling.
- Published
- 2023
- Full Text
- View/download PDF
10. Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis.
- Author
-
Evans JF, McCormack FX, Sonenberg N, and Krymskaya VP
- Subjects
- Female, Humans, Eukaryotic Initiation Factor-4E genetics, Eukaryotic Initiation Factor-4E metabolism, TOR Serine-Threonine Kinases metabolism, Mechanistic Target of Rapamycin Complex 1 metabolism, Sirolimus pharmacology, Lymphangioleiomyomatosis diagnosis, Lymphangioleiomyomatosis drug therapy, Lymphangioleiomyomatosis genetics
- Abstract
Lymphangioleiomyomatosis (LAM) is a cystic lung disease of women resulting from mutations in tuberous sclerosis complex (TSC) genes that suppress the mammalian target of rapamycin complex 1 (mTORC1) pathway. mTORC1 activation enhances a plethora of anabolic cellular functions, mainly via the activation of mRNA translation through stimulation of ribosomal protein S6 kinase (S6K1)/ribosomal protein S6 (S6) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1)/eukaryotic translation initiation factor 4E (eIF4E). Rapamycin (sirolimus), an allosteric inhibitor of mTORC1, stabilises lung function in many but not all LAM patients and, upon cessation of the drug, disease progression resumes. At clinically tolerable concentrations, rapamycin potently inhibits the ribosomal S6K1/S6 translation ribosome biogenesis and elongation axis, but not the translation 4E-BP1/eIF4E initiation axis. In this mini-review, we propose that inhibition of mTORC1-driven translation initiation is an obvious but underappreciated therapeutic strategy in LAM, TSC and other mTORC1-driven diseases., Competing Interests: Conflict of interest: No author has a conflict of interest., (Copyright ©The authors 2023.)
- Published
- 2023
- Full Text
- View/download PDF
11. Mesenchymal Stem Cell Regulation of Macrophage Phagocytosis; Quantitation and Imaging.
- Author
-
Evans JF, Ricigliano AE, Morante AV, Martinez E, Vargas D, and Thyagaraj J
- Subjects
- Coculture Techniques, Macrophages, Phagocytosis, Zymosan pharmacology, Mesenchymal Stem Cells
- Abstract
Mesenchymal stem cells (MSC) have traditionally been studied for their regenerative properties, but more recently, their immunoregulatory characteristics have been at the forefront. They interact with and regulate immune cell activity. The focus of this study is the MSC regulation of macrophage phagocytic activity. Macrophage (MΦ) phagocytosis is an important part of the innate immune system response to infection, and the mechanisms through which MSC modulate this response are under active investigation. Presented here is a method to study MΦ phagocytosis of non-opsonized zymosan particles conjugated to a pH-sensitive fluorescent molecule while in co-culture with MSC. As phagocytic activity increases and the labeled zymosan particles are enclosed within the acidic environment of the phagolysosome, the fluorescence intensity of the pH-sensitive molecule increases. With the appropriate excitation and emission wavelengths, phagocytic activity is measured using a fluorescent spectrophotometer and kinetic data is presented as changes in relative fluorescent units over a 70 min period. To support this quantitative data, the change in the phagocytic activity is visualized using dynamic imaging. Results using this method demonstrate that when in co-culture, MSC enhance MΦ phagocytosis of non-opsonized zymosan of both naive and IFN-γ treated MΦ. These data add to the current knowledge of MSC regulation of the innate immune system. This method can be applied in future investigations to fully delineate the underlying cellular and molecular mechanisms.
- Published
- 2021
- Full Text
- View/download PDF
12. CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis.
- Author
-
Evans JF, Obraztsova K, Lin SM, and Krymskaya VP
- Subjects
- Animals, Humans, Lymphangioleiomyomatosis drug therapy, Lymphangioleiomyomatosis metabolism, Lymphangioleiomyomatosis physiopathology, Molecular Targeted Therapy, TOR Serine-Threonine Kinases metabolism, Wnt Proteins metabolism
- Abstract
The mechanistic target of rapamycin (mTOR) and wingless-related integration site (Wnt) signal transduction networks are evolutionarily conserved mammalian growth and cellular development networks. Most cells express many of the proteins in both pathways, and this review will briefly describe only the key proteins and their intra- and extracellular crosstalk. These complex interactions will be discussed in relation to cancer development, drug resistance, and stem cell exhaustion. This review will also highlight the tumor-suppressive tuberous sclerosis complex (TSC) mutated, mTOR-hyperactive lung disease of women, lymphangioleiomyomatosis (LAM). We will summarize recent advances in the targeting of these pathways by monotherapy or combination therapy, as well as future potential treatments.
- Published
- 2021
- Full Text
- View/download PDF
13. The Utility of Verbal Therapy for Pediatric Cancer Patients and Survivors: Expressive Writing, Video Narratives, and Bibliotherapy Exercises.
- Author
-
Jones JK, Evans JF, and Barfield RC
- Abstract
Childhood cancer is a stressful experience. No pediatric patient, however, should be made to feel as if their concerns and feelings about their cancer experience must be bottled up inside. Importantly, talking and writing about one's illness has myriad implications for young cancer patients and survivors. The most salient of these may include increased understanding of one's condition as well as improved physical and cognitive symptoms (e.g., lowered depression, decreased anxiety, and an enhanced quality of life overall). This literature review explores three promising avenues for verbal therapy in the pediatric oncology setting: expressive writing, video narratives, and bibliotherapy exercises. Several recent studies, covering verbal therapy methods from illness blogging to book interventions, are referenced and discussed. Ultimately, we conclude that expressive writing, video narratives, and bibliotherapy exercises are valuable, feasible, inexpensive, and acceptable tools for patients and survivors of childhood cancer to facilitate self-expression-and to find meaning in the uncertainty and anxiety that cancer inherently fosters. We recommend that future studies investigate this theme so that we may improve quality of life and mental health for pediatric cancer patients and survivors worldwide., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Jones, Evans and Barfield.)
- Published
- 2021
- Full Text
- View/download PDF
14. Montelukast Use Decreases Cardiovascular Events in Asthmatics.
- Author
-
Hoxha M, Tedesco CC, Quaglin S, Malaj V, Pustina L, Capra V, Evans JF, Sala A, and Rovati GE
- Abstract
Cysteinyl leukotrienes are proinflammatory mediators with a clinically established role in asthma and a human genetic and preclinical role in cardiovascular pathology. Given that cardiovascular disease has a critical inflammatory component, the aim of this work was to conduct an observational study to verify whether the use of a cysteinyl leukotriene antagonist, namely, montelukast, may protect asthmatic patients from a major cardiovascular event and, therefore, represent an innovative adjunct therapy to target an inflammatory component in cardiovascular disease. We performed an observational retrospective 3-year study on eight hundred adult asthmatic patients 18 years or older in Albania, equally distributed into two cohorts, exposed or nonexposed to montelukast usage, matched by age and gender according to information reported in the data collection. Patients with a previous history of myocardial infarction or ischemic stroke were excluded. In summary, 37 (4.6%) of the asthmatic patients, 32 nonexposed, and five exposed to montelukast suffered a major cardiovascular event during the 3-year observation period. All the cardiovascular events, in either group, occurred among patients with an increased cardiovascular risk. Our analyses demonstrate that, independent from gender, exposure to montelukast remained a significant protective factor for incident ischemic events (78% or 76% risk reduction depending on type of analysis). The event-free Kaplan-Meier survival curves confirmed the lower cardiovascular event incidence in patients exposed to montelukast. Our data suggest that there is a potential preventative role of montelukast for incident cardiac ischemic events in the older asthmatic population, indicating a comorbidity benefit of montelukast usage in asthmatics by targeting cysteinyl leukotriene-driven cardiac disease inflammation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling Editor declared a shared affiliation, though no other collaboration, with one of the authors JE., (Copyright © 2021 Hoxha, Tedesco, Quaglini, Malaj, Pustina, Capra, Evans, Sala and Rovati.)
- Published
- 2021
- Full Text
- View/download PDF
15. mTORC1 activation in lung mesenchyme drives sex- and age-dependent pulmonary structure and function decline.
- Author
-
Obraztsova K, Basil MC, Rue R, Sivakumar A, Lin SM, Mukhitov AR, Gritsiuta AI, Evans JF, Kopp M, Katzen J, Robichaud A, Atochina-Vasserman EN, Li S, Carl J, Babu A, Morley MP, Cantu E, Beers MF, Frank DB, Morrisey EE, and Krymskaya VP
- Subjects
- Age Factors, Aged, Animals, Female, Humans, Lung drug effects, Lung physiopathology, Lymphangioleiomyomatosis drug therapy, Lymphangioleiomyomatosis genetics, Lymphangioleiomyomatosis physiopathology, Male, Mechanistic Target of Rapamycin Complex 1 genetics, Mesoderm drug effects, Mice, Sex Factors, Sirolimus administration & dosage, Tuberous Sclerosis Complex 2 Protein genetics, Tuberous Sclerosis Complex 2 Protein metabolism, Wnt Signaling Pathway, Lung metabolism, Lymphangioleiomyomatosis metabolism, Mechanistic Target of Rapamycin Complex 1 metabolism, Mesoderm metabolism
- Abstract
Lymphangioleiomyomatosis (LAM) is a rare fatal cystic lung disease due to bi-allelic inactivating mutations in tuberous sclerosis complex (TSC1/TSC2) genes coding for suppressors of the mechanistic target of rapamycin complex 1 (mTORC1). The origin of LAM cells is still unknown. Here, we profile a LAM lung compared to an age- and sex-matched healthy control lung as a hypothesis-generating approach to identify cell subtypes that are specific to LAM. Our single-cell RNA sequencing (scRNA-seq) analysis reveals novel mesenchymal and transitional alveolar epithelial states unique to LAM lung. This analysis identifies a mesenchymal cell hub coordinating the LAM disease phenotype. Mesenchymal-restricted deletion of Tsc2 in the mouse lung produces a mTORC1-driven pulmonary phenotype, with a progressive disruption of alveolar structure, a decline in pulmonary function, increase of rapamycin-sensitive expression of WNT ligands, and profound female-specific changes in mesenchymal and epithelial lung cell gene expression. Genetic inactivation of WNT signaling reverses age-dependent changes of mTORC1-driven lung phenotype, but WNT activation alone in lung mesenchyme is not sufficient for the development of mouse LAM-like phenotype. The alterations in gene expression are driven by distinctive crosstalk between mesenchymal and epithelial subsets of cells observed in mesenchymal Tsc2-deficient lungs. This study identifies sex- and age-specific gene changes in the mTORC1-activated lung mesenchyme and establishes the importance of the WNT signaling pathway in the mTORC1-driven lung phenotype.
- Published
- 2020
- Full Text
- View/download PDF
16. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
- Author
-
Evans JF, Rue RW, Mukhitov AR, Obraztsova K, Smith CJ, and Krymskaya VP
- Subjects
- Cell Line, Tumor, Cell Proliferation drug effects, Gene Expression Regulation, Neoplastic drug effects, Humans, Intracellular Signaling Peptides and Proteins antagonists & inhibitors, Protein Serine-Threonine Kinases antagonists & inhibitors, Pyridazines, Quinolines pharmacology, Sirolimus pharmacology, Sulfonamides pharmacology, Phosphatidylinositol 3-Kinases metabolism, Phosphoinositide-3 Kinase Inhibitors pharmacology, TOR Serine-Threonine Kinases antagonists & inhibitors, Tuberous Sclerosis Complex 2 Protein deficiency
- Abstract
Lymphangioleiomyomatosis (LAM) is a rare metastatic cystic lung disease due to a mutation in a TSC tumor suppressor, resulting in hyperactive mTOR growth pathways. Sirolimus (rapamycin), an allosteric mTORC1 inhibitor, is a therapeutic option for women with LAM but it only maintains lung volume during treatment and does not provide benefit for all LAM patients. The two major mTORC1 protein synthesis pathways are via S6K/S6 or 4E-BP/eIF4E activation. We aimed to investigate rapamycin in combination with compounds that target associated growth pathways, with the potential to be additive to rapamycin. In this study we demonstrated that rapamycin, at a clinically tolerable concentration (10 nM), inhibited the phosphorylation of S6, but not the critical eIF4E releasing Thr 37/46 phosphorylation sites of 4E-BP1 in TSC2-deficient LAM-derived cells. We also characterized the abundant protein expression of peIF4E within LAM lesions. A selective MNK1/2 inhibitor eFT508 inhibited the phosphorylation of eIF4E but did not reduce TSC2-null cell growth. In contrast, a PI3K/mTOR inhibitor omipalisib blocked the phosphorylation of Akt and both S6K/S6 and 4E-BP/eIF4E branches, and additively decreased the growth of TSC2-null cells with rapamycin. Omipalisib, or another inhibitor of both major mTORC1 growth pathways and pAkt, might provide therapeutic options for TSC2-deficient cancers including, but not limited to, LAM., Competing Interests: The authors declare no conflict of interest.
- Published
- 2019
- Full Text
- View/download PDF
17. Corrigendum to "Mouse Mesenchymal Progenitor Cells Expressing Adipogenic and Osteogenic Transcription Factors Suppress the Macrophage Inflammatory Response".
- Author
-
Fernandez N, Renna H, McHugh L, Mazalkova K, Crugnola W, and Evans JF
- Abstract
[This corrects the article DOI: 10.1155/2017/5846257.].
- Published
- 2019
- Full Text
- View/download PDF
18. Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.
- Author
-
Himes BE, Obraztsova K, Lian L, Shumyatcher M, Rue R, Atochina-Vasserman EN, Hur SK, Bartolomei MS, Evans JF, and Krymskaya VP
- Subjects
- Animals, Cell Line, Tumor, Embryo, Mammalian pathology, Fibroblasts pathology, Humans, Insulin-Like Growth Factor II genetics, Lung Neoplasms genetics, Lung Neoplasms pathology, Lymphangioleiomyomatosis, Mice, Mice, Knockout, Tuberous Sclerosis Complex 2 Protein, Embryo, Mammalian metabolism, Fibroblasts metabolism, Gene Expression Regulation, Neoplastic, Insulin-Like Growth Factor II biosynthesis, Lung Neoplasms metabolism, Signal Transduction, Sirolimus pharmacology, Tumor Suppressor Proteins deficiency
- Abstract
Lymphangioleiomyomatosis (LAM) is a rare, almost exclusively female lung disease linked to inactivating mutations in tuberous sclerosis complex 2 (TSC2), a tumor suppressor gene that controls cell metabolic state and growth via regulation of the mechanistic target of rapamycin (mTORC1) signaling. mTORC1 is frequently activated in human cancers and, although the mTORC1 inhibitor rapamycin has a cytostatic effect, it is, in general, unable to elicit a robust curative effect or tumor regression. Using RNA-Seq, we identified (1) Insulin-like Growth Factor (IGF2) as one of the genes with the highest fold-change difference between human TSC2-null and TSC2-expressing angiomyolipoma cells from a patient with LAM, and (2) the mouse IGF2 homolog Igf2, as a top-ranking gene according to fold change between Tsc2-/- and Tsc2+/+ mouse embryo fibroblasts (MEFs). We extended transcript-level findings to protein level, observing increased Igf2 protein expression and Igf2 secretion by Tsc2-/- MEFs. Increased Igf2 expression was not due to epigenetic imprinting, but was partially mediated through the Stat3 pathway and was completely insensitive to rapamycin treatment. An siRNA-mediated decrease of Igf2 resulted in decreased Stat3 phosphorylation, suggesting presence of an autocrine Igf2/Stat3 amplification cycle in Tsc2-/- MEFs. In human pulmonary LAM lesions and metastatic cell clusters, high levels of IGF2 were associated with mTORC1 activation. In addition, treatment of three primary IGF2-expressing LAM lung cell lines with rapamycin did not result in IGF2 level changes. Thus, targeting of IGF2 signaling may be of therapeutic value to LAM patients, particularly those who are unresponsive to rapamycin.
- Published
- 2018
- Full Text
- View/download PDF
19. Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
- Author
-
Rowbottom MW, Bain G, Calderon I, Lasof T, Lonergan D, Lai A, Huang F, Darlington J, Prodanovich P, Santini AM, King CD, Goulet L, Shannon KE, Ma GL, Nguyen K, MacKenna DA, Evans JF, and Hutchinson JH
- Subjects
- Administration, Oral, Amino Acid Oxidoreductases metabolism, Animals, Disease Models, Animal, Enzyme Inhibitors administration & dosage, Enzyme Inhibitors therapeutic use, Fibrosis, Halogenation, Humans, Lung drug effects, Lung enzymology, Lung pathology, Lung Diseases drug therapy, Lung Diseases enzymology, Lung Diseases pathology, Male, Methylation, Mice, Inbred C57BL, Models, Molecular, Pyridines administration & dosage, Pyridines therapeutic use, Structure-Activity Relationship, Amino Acid Oxidoreductases antagonists & inhibitors, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacology, Pyridines chemistry, Pyridines pharmacology
- Abstract
LOXL2 catalyzes the oxidative deamination of ε-amines of lysine and hydroxylysine residues within collagen and elastin, generating reactive aldehydes (allysine). Condensation with other allysines or lysines drives the formation of inter- and intramolecular cross-linkages, a process critical for the remodeling of the ECM. Dysregulation of this process can lead to fibrosis, and LOXL2 is known to be upregulated in fibrotic tissue. Small-molecules that directly inhibit LOXL2 catalytic activity represent a useful option for the treatment of fibrosis. Herein, we describe optimization of an initial hit 2, resulting in identification of racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone 28, a potent irreversible inhibitor of LOXL2 that is highly selective over LOX and other amine oxidases. Oral administration of 28 significantly reduced fibrosis in a 14-day mouse lung bleomycin model. The (R,R)-enantiomer 43 (PAT-1251) was selected as the clinical compound which has progressed into healthy volunteer Phase 1 trials, making it the "first-in-class" small-molecule LOXL2 inhibitor to enter clinical development.
- Published
- 2017
- Full Text
- View/download PDF
20. Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
- Author
-
Hutchinson JH, Rowbottom MW, Lonergan D, Darlington J, Prodanovich P, King CD, Evans JF, and Bain G
- Abstract
Two series of novel LOXL2 enzyme inhibitors are described: benzylamines substituted with electron withdrawing groups at the para -position and 2-substituted pyridine-4-ylmethanamines. The most potent compound, (2-chloropyridin-4-yl)methanamine 20 (hLOXL2 IC
50 = 126 nM), was shown to be selective for LOXL2 over LOX and three other amine oxidases (MAO-A, MAO-B, and SSAO). Compound 20 is the first published small molecule inhibitor selective for LOXL2 over LOX.- Published
- 2017
- Full Text
- View/download PDF
21. Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
- Author
-
Bain G, Shannon KE, Huang F, Darlington J, Goulet L, Prodanovich P, Ma GL, Santini AM, Stein AJ, Lonergan D, King CD, Calderon I, Lai A, Hutchinson JH, and Evans JF
- Subjects
- Animals, Disease Models, Animal, Enzyme Inhibitors pharmacokinetics, Enzyme Inhibitors therapeutic use, Female, Humans, Male, Mice, Piperazines pharmacokinetics, Piperazines therapeutic use, Enzyme Inhibitors pharmacology, Liver Cirrhosis drug therapy, Liver Cirrhosis enzymology, Phosphoric Diester Hydrolases metabolism, Piperazines pharmacology
- Abstract
Autotaxin (ATX) is a secreted glycoprotein that converts lysophosphatidylcholine (LPC) to the bioactive phospholipid lysophosphatidic acid (LPA) and is the major enzyme generating circulating LPA. Inhibition of LPA signaling has profound antifibrotic effects in multiple organ systems, including lung, kidney, skin, and peritoneum. However, other LPA-generating pathways exist, and the role of ATX in localized tissue LPA production and fibrosis remains unclear and controversial. In this study, we describe the preclinical pharmacologic, pharmacokinetic, and pharmacodynamic properties of a novel small-molecule ATX inhibitor, PAT-505 [3-((6-chloro-2-cyclopropyl-1-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-1H-indol-3-yl) thio)-2-fluorobenzoic acid sodium salt]. PAT-505 is a potent, selective, noncompetitive inhibitor that displays significant inhibition of ATX activity in plasma and liver tissue after oral administration. When dosed therapeutically in a Stelic Mouse Animal Model of nonalcoholic steatohepatitis (NASH), PAT-505 treatment resulted in a small but significant improvement in fibrosis with only minor improvements in hepatocellular ballooning and hepatic inflammation. In a choline-deficient, high-fat diet model of NASH, therapeutic treatment with PAT-505 robustly reduced liver fibrosis with no significant effect on steatosis, hepatocellular ballooning, or inflammation. These data demonstrate that inhibiting autotaxin is antifibrotic and may represent a novel therapeutic approach for the treatment of multiple fibrotic liver diseases, including NASH., (Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2017
- Full Text
- View/download PDF
22. Mouse Mesenchymal Progenitor Cells Expressing Adipogenic and Osteogenic Transcription Factors Suppress the Macrophage Inflammatory Response.
- Author
-
Fernandez N, Renna H, McHugh L, Mazalkova K, Crugnola W, and Evans JF
- Abstract
Mesenchymal progenitor cell characteristics that can identify progenitor populations with specific functions in immunity are actively being investigated. Progenitors from bone marrow and adipose tissue regulate the macrophage (MΦ) inflammatory response by promoting the switch from an inflammatory to an anti-inflammatory phenotype. Conversely, mesenchymal progenitors from the mouse aorta (mAo) support and contribute to the MΦ response under inflammatory conditions. We used cell lines with purported opposing immune-regulatory function, a bone marrow derived mesenchymal progenitor cell line (D1) and a mouse aorta derived mesenchymal progenitor cell line (mAo). Their interaction and regulation of the MΦ cell response to the inflammatory mediator, lipopolysaccharide (LPS), was examined by coculture. As expected, D1 cells suppressed NO, TNF- α , and IL-12p70 production but MΦ phagocytic activity remained unchanged. The mAo cells enhanced NO and TNF- α production in coculture and enhanced MΦ phagocytic activity. Using flow cytometry and PCR array, we then sought to identify sets of MSC-associated genes and markers that are expressed by these progenitor populations. We have determined that immune-supportive mesenchymal progenitors highly express chondrogenic and tenogenic transcription factors while immunosuppressive mesenchymal progenitors highly express adipogenic and osteogenic transcription factors. These data will be useful for the isolation, purification, and modification of mesenchymal progenitors to be used in the treatment of inflammatory diseases., Competing Interests: The authors declare that there is no conflict of interests regarding the publication of this paper.
- Published
- 2017
- Full Text
- View/download PDF
23. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
- Author
-
Sun Y, Zhang W, Evans JF, Floreani A, Zou Z, Nishio Y, Qi R, Leung PS, Bowlus CL, and Gershwin ME
- Subjects
- Animals, Biosynthetic Pathways, Humans, Phosphoric Diester Hydrolases chemistry, Phosphoric Diester Hydrolases genetics, Cholangitis pathology, Lysophospholipids biosynthesis, Phosphoric Diester Hydrolases metabolism, Pruritus metabolism
- Abstract
Autotaxin (ATX) is a 125-kD type II ectonucleotide pyrophosphatase/phosphodiesterase (ENPP2 or NPP2) originally discovered as an unknown "autocrine motility factor" in human melanoma cells. In addition to its pyrophosphatase/phosphodiesterase activities ATX has lysophospholipase D (lysoPLD) activity, catalyzing the conversion of lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). ATX is the only ENPP family member with lysoPLD activity and it produces most of the LPA in circulation. In support of this, ATX heterozygous mice have 50% of normal LPA plasma levels. The ATX-LPA signaling axis plays an important role in both normal physiology and disease pathogenesis and recently has been linked to pruritus in chronic cholestatic liver diseases, including primary biliary cholangitis (PBC). Several lines of evidence have suggested that a circulating puritogen is responsible, but the identification of the molecule has yet to be definitively identified. In contrast, plasma ATX activity is strongly associated with pruritus in PBC, suggesting a targetable molecule for treatment. We review herein the biochemistry of ATX and the rationale for its role in pruritus., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
24. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
- Author
-
Stein AJ, Bain G, Prodanovich P, Santini AM, Darlington J, Stelzer NM, Sidhu RS, Schaub J, Goulet L, Lonergan D, Calderon I, Evans JF, and Hutchinson JH
- Subjects
- Animals, Cell Line, Tumor, Crystallization, HEK293 Cells, Humans, Mice, Protein Binding physiology, Protein Structure, Secondary, Protein Structure, Tertiary, Structure-Activity Relationship, Enzyme Inhibitors chemistry, Enzyme Inhibitors metabolism, Phosphoric Diester Hydrolases chemistry, Phosphoric Diester Hydrolases metabolism
- Abstract
Autotaxin (ATX) is a secreted enzyme that hydrolyzes lysophosphatidylcholine to lysophosphatidic acid (LPA). LPA is a bioactive phospholipid that regulates diverse biological processes, including cell proliferation, migration, and survival/apoptosis, through the activation of a family of G protein-coupled receptors. The ATX-LPA pathway has been implicated in many pathologic conditions, including cancer, fibrosis, inflammation, cholestatic pruritus, and pain. Therefore, ATX inhibitors represent an attractive strategy for the development of therapeutics to treat a variety of diseases. Mouse and rat ATX have been crystallized previously with LPA or small-molecule inhibitors bound. Here, we present the crystal structures of human ATX in complex with four previously unpublished, structurally distinct ATX inhibitors. We demonstrate that the mechanism of inhibition of each compound reflects its unique interactions with human ATX. Our studies may provide a basis for the rational design of novel ATX inhibitors., (Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2015
- Full Text
- View/download PDF
25. Mouse aorta-derived mesenchymal progenitor cells contribute to and enhance the immune response of macrophage cells under inflammatory conditions.
- Author
-
Evans JF, Salvador V, George S, Trevino-Gutierrez C, and Nunez C
- Subjects
- Animals, Bone Marrow Cells cytology, Bone Marrow Cells immunology, Cell Differentiation immunology, Cell Line, Endothelial Cells cytology, Interferon-gamma, Interleukin-6 metabolism, Lipopolysaccharides, Lipoproteins, LDL metabolism, Male, Mesenchymal Stem Cells cytology, Mice, Mice, Inbred C3H, Mice, Inbred C57BL, Nitric Oxide metabolism, Tumor Necrosis Factor-alpha metabolism, Aorta cytology, Endothelial Cells immunology, Inflammation immunology, Macrophages immunology, Mesenchymal Stem Cells immunology
- Abstract
Introduction: Mesenchymal progenitor cells interact with immune cells and modulate inflammatory responses. The cellular characteristics required for this modulation are under fervent investigation. Upon interaction with macrophage cells, they can contribute to or suppress an inflammatory response. Current studies have focused on mesenchymal progenitors derived from bone marrow, adipose, and placenta. However, the arterial wall contains many mesenchymal progenitor cells, which during vascular disease progression have the potential to interact with macrophage cells. To examine the consequence of vascular-tissue progenitor cell-macrophage cell interactions in an inflammatory environment, we used a recently established mesenchymal progenitor cell line derived from the mouse aorta., Methods: Mouse bone marrow-derived macrophage (MΦ) cells and mouse aorta-derived mesenchymal progenitor (mAo) cells were cultured alone or co-cultured directly and indirectly. Cells were treated with oxidized low-density lipoprotein (ox-LDL) or exposed to the inflammatory mediators lipopolysaccharide (LPS) and interferon-gamma (IFNγ) or both. A Toll-like receptor-4 (TLR4)-deficient macrophage cell line was used to determine the role of the mAo cells. To monitor inflammation, nitric oxide (NO), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNFα) secretions were measured., Results: Mesenchymal progenitor cells isolated from aorta and cloned by high proliferative capacity (mAo) can differentiate into multiple mesenchymal lineages and are positive for several commonly used mouse mesenchymal stem cell markers (that is, CD29, CD44, CD105, CD106, and Sca-1) but are negative for CD73 and ecto-5'-nucleotidase. In co-culture with MΦ cells, they increase MΦ oxidized-LDL uptake by 52.2%. In an inflammatory environment, they synergistically and additively contribute to local production of both NO and IL-6. After exposure to ox-LDL, the inflammatory response of MΦ cells to LPS and LPS/IFNγ is muted. However, when lipid-laden MΦ cells are co-cultured with mAo cell progenitors, the muted response is recovered and the contribution by the mAo cell progenitor is dependent upon cell contact., Conclusions: The resident mesenchymal progenitor cell is a potential contributor to vascular inflammation when in contact with inflamed and lipid-laden MΦ cells. This interaction represents an additional target in vascular disease treatment. The potential for resident cells to contribute to the local immune response should be considered when designing therapeutics targeting inflammatory vascular disease.
- Published
- 2015
- Full Text
- View/download PDF
26. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
- Author
-
Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, and Chopra R
- Subjects
- Adaptive Immunity drug effects, Animals, B-Lymphocytes drug effects, B-Lymphocytes immunology, B-Lymphocytes metabolism, Cell Line, Cyclic AMP metabolism, Cyclic Nucleotide Phosphodiesterases, Type 4 chemistry, Cyclic Nucleotide Phosphodiesterases, Type 4 metabolism, Cytokines metabolism, Disease Models, Animal, Female, Ferrets, Humans, Jurkat Cells, Lung Diseases drug therapy, Male, Mice, Mice, Transgenic, Phosphodiesterase 4 Inhibitors metabolism, Phosphodiesterase 4 Inhibitors therapeutic use, Protein Binding, T-Lymphocytes drug effects, T-Lymphocytes immunology, T-Lymphocytes metabolism, Thalidomide metabolism, Thalidomide pharmacology, Thalidomide therapeutic use, Vomiting prevention & control, Immunity, Innate drug effects, Phosphodiesterase 4 Inhibitors pharmacology, Thalidomide analogs & derivatives
- Abstract
Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in psoriasis, psoriatic arthropathies, and Behçet's syndrome. In March 2014, the US Food and Drug Administration approved apremilast for the treatment of adult patients with active psoriatic arthritis. The properties of apremilast were evaluated to determine its specificity, effects on intracellular signaling, gene and protein expression, and in vivo pharmacology using models of innate and adaptive immunity. Apremilast inhibited PDE4 isoforms from all four sub-families (A1A, B1, B2, C1, and D2), with IC50 values in the range of 10 to 100 nM. Apremilast did not significantly inhibit other PDEs, kinases, enzymes, or receptors. While both apremilast and thalidomide share a phthalimide ring structure, apremilast lacks the glutarimide ring and thus fails to bind to cereblon, the target of thalidomide action. In monocytes and T cells, apremilast elevated intracellular cAMP and induced phosphorylation of the protein kinase A substrates CREB and activating transcription factor-1 while inhibiting NF-κB transcriptional activity, resulting in both up- and down-regulation of several genes induced via TLR4. Apremilast reduced interferon-α production by plasmacytoid dendritic cells and inhibited T-cell cytokine production, but had little effect on B-cell immunoglobulin secretion. In a transgenic T-cell and B-cell transfer murine model, apremilast (5mg/kg/day p.o.) did not affect clonal expansion of either T or B cells and had little or no effect on their expression of activation markers. The effect of apremilast on innate immunity was tested in the ferret lung neutrophilia model, which allows monitoring of the known PDE4 inhibitor gastrointestinal side effects (nausea and vomiting). Apremilast significantly inhibited lung neutrophilia at 1mg/kg, but did not induce significant emetic reflexes at doses <30 mg/kg. Overall, the pharmacological effects of apremilast are consistent with those of a targeted PDE4 inhibitor, with selective effects on innate immune responses and a wide therapeutic index compared to its gastrointestinal side effects., (Copyright © 2014. Published by Elsevier Inc.)
- Published
- 2014
- Full Text
- View/download PDF
27. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.
- Author
-
Bäck M, Powell WS, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, and Rovati GE
- Subjects
- Animals, Humans, Ligands, Receptors, Eicosanoid agonists, Receptors, Eicosanoid antagonists & inhibitors, Signal Transduction, Receptors, Eicosanoid metabolism
- Abstract
The endogenous ligands for the LT, lipoxin (LX) and oxoeicosanoid receptors are bioactive products produced by the action of the lipoxygenase family of enzymes. The LT receptors BLT1 and BLT2 , are activated by LTB4 and the CysLT1 and CysLT2 receptors are activated by the cysteinyl-LTs, whereas oxoeicosanoids exert their action through the OXE receptor. In contrast to these pro-inflammatory mediators, LXA4 transduces responses associated with the resolution of inflammation through the receptor FPR2/ALX (ALX/FPR2). The aim of the present review is to give a state of the field on these receptors, with focus on recent important findings. For example, BLT1 receptor signalling in cancer and the dual role of the BLT2 receptor in pro- and anti-inflammatory actions have added more complexity to lipid mediator signalling. Furthermore, a cross-talk between the CysLT and P2Y receptor systems has been described, and also the presence of novel receptors for cysteinyl-LTs, such as GPR17 and GPR99. Finally, lipoxygenase metabolites derived from ω-3 essential polyunsaturated acids, the resolvins, activate the receptors GPR32 and ChemR23. In conclusion, the receptors for the lipoxygenase products make up a sophisticated and tightly controlled system of endogenous pro- and anti-inflammatory signalling in physiology and pathology., (© 2014 The British Pharmacological Society.)
- Published
- 2014
- Full Text
- View/download PDF
28. ACTH promotes chondrogenic nodule formation and induces transient elevations in intracellular calcium in rat bone marrow cell cultures via MC2-R signaling.
- Author
-
Evans JF, Rodriguez S, and Ragolia L
- Subjects
- Animals, Bone Marrow Cells cytology, Chondrogenesis drug effects, Membrane Proteins biosynthesis, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells drug effects, Mesenchymal Stem Cells metabolism, Pro-Opiomelanocortin metabolism, Rats, Rats, Inbred WKY, Adrenocorticotropic Hormone pharmacology, Bone Marrow Cells drug effects, Bone Marrow Cells metabolism, Calcium metabolism, Receptor, Melanocortin, Type 2 metabolism
- Abstract
Adrenocorticotropic hormone (ACTH) is among several melanocortin peptide hormones that are derived from proopiomelanocortin (POMC). ACTH has been found to enhance osteogenesis and chondrogenesis. We show that, in the presence of dexamethasone, ACTH dose-dependently increases chondrogenic nodule formation in bone marrow stromal cells (BMSC) from the Wistar Kyoto (WKY) rat. The nodules consist in condensed cells highly expressing alkaline phosphatase, Sox9 and type II collagen transcripts and a proteoglycan-rich matrix. Immunoblot analysis of crude membrane fractions has shown that these cells express three melanocortin receptors (MC-R), namely MC2-R, MC3-R and MC5-R and the melanocortin 2-receptor accessory protein (MRAP). To determine which of these receptors mediate ACTH-induced effects, we have used MC-R-specific peptides and the known agonist profiles of the receptors. Neither α-MSH, a strong agonist of MC5-R, nor γ2-MSH, a strong agonist of MC3-R, duplicates ACTH effects in rat BMSC. In addition, calcium flux has been examined as a mechanism for ACTH action at the MC2-R. Consistent with MC2-R and MRAP expression patterns in the BMSC cultures, ACTH-induced transient increases in intracellular calcium are increased with dexamethasone treatment. Neither α-MSH nor γ2-MSH affects calcium flux. Dexamethasone increases MC2-R and MRAP expression and POMC peptide expression and cleavage increasing the production of the lipolytic β-lipotropic hormone product. Therefore, the effects of ACTH in rat BMSC enriched for mesenchymal progenitors are consistent with an MC2-R signaling mechanism, with dexamethasone being capable of regulating components of the melanocortin system in these cells.
- Published
- 2013
- Full Text
- View/download PDF
29. Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
- Author
-
Bain G, King CD, Schaab K, Rewolinski M, Norris V, Ambery C, Bentley J, Yamada M, Santini AM, van de Wetering de Rooij J, Stock N, Zunic J, Hutchinson JH, and Evans JF
- Subjects
- Administration, Oral, Adolescent, Adult, Aged, Area Under Curve, Asian People, Biomarkers blood, Biomarkers urine, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Leukotriene B4 blood, Leukotriene B4 urine, Leukotriene E4 urine, Male, Middle Aged, White People, Young Adult, 5-Lipoxygenase-Activating Protein Inhibitors adverse effects, 5-Lipoxygenase-Activating Protein Inhibitors pharmacokinetics, 5-Lipoxygenase-Activating Protein Inhibitors pharmacology, Indoles adverse effects, Indoles pharmacokinetics, Indoles pharmacology, Leukotriene E4 blood, Pentanoic Acids adverse effects, Pentanoic Acids pharmacokinetics, Pentanoic Acids pharmacology
- Abstract
Aim: To assess the pharmacokinetics, pharmacodynamics, safety and tolerability of the 5-lipoxygenase-activating protein inhibitor, GSK2190915, after oral dosing in two independent phase I studies, one in Western European and one in Japanese subjects, utilizing different formulations., Method: Western European subjects received single (50-1000 mg) or multiple (10-450 mg) oral doses of GSK2190915 or placebo in a dose-escalating manner. Japanese subjects received three of four GSK2190915 doses (10-200 mg) plus placebo once in a four period crossover design. Blood samples were collected for GSK2190915 concentrations and blood and urine were collected to measure leukotriene B₄ and leukotriene E₄, respectively, as pharmacodynamic markers of drug activity., Results: There was no clear difference in adverse events between placebo and active drug-treated subjects in either study. Maximum plasma concentrations of GSK2190915 and area under the curve increased in a dose-related manner and mean half-life values ranged from 16-34 h. Dose-dependent inhibition of blood leukotriene B₄ production was observed and near complete inhibition of urinary leukotriene E₄ excretion was shown at all doses except the lowest dose. The EC₅₀ values for inhibition of LTB₄ were 85 nM and 89 nM in the Western European and Japanese studies, respectively., Conclusion: GSK2190915 is well-tolerated with pharmacokinetics and pharmacodynamics in Western European and Japanese subjects that support once daily dosing for 24 h inhibition of leukotrienes. Doses of ≥50 mg show near complete inhibition of urinary leukotriene E₄ at 24 h post-dose, whereas doses of ≥150 mg are required for 24 h inhibition of blood LTB₄., (© 2012 GlaxoSmithKline. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.)
- Published
- 2013
- Full Text
- View/download PDF
30. The lipocalin-type prostaglandin D2 synthase knockout mouse model of insulin resistance and obesity demonstrates early hypothalamic-pituitary-adrenal axis hyperactivity.
- Author
-
Evans JF, Islam S, Urade Y, Eguchi N, and Ragolia L
- Subjects
- Adrenocorticotropic Hormone blood, Animals, Corticosterone blood, Genotype, Hypercholesterolemia genetics, Hypercholesterolemia metabolism, Hyperglycemia genetics, Hyperglycemia metabolism, Insulin Resistance genetics, Intramolecular Oxidoreductases genetics, Leptin blood, Lipocalins genetics, Metabolic Syndrome genetics, Metabolic Syndrome metabolism, Mice, Mice, Inbred C57BL, Mice, Knockout, Obesity genetics, Hypothalamo-Hypophyseal System metabolism, Insulin Resistance physiology, Intramolecular Oxidoreductases metabolism, Lipocalins metabolism, Obesity metabolism, Pituitary-Adrenal System metabolism
- Abstract
Obesity and diabetes are closely associated with hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis. In this study, the diet-induced obese C57BL/6 mouse was used to test the hypothesis that chronically elevated metabolic parameters associated with the development of obesity such as cholesterol and glucose can aggravate basal HPA axis activity. Because the lipocalin-type prostaglandin D(2) synthase (L-PGDS) knockout (KO) mouse is a model of accelerated insulin resistance, glucose intolerance, and obesity, it was further hypothesized that HPA activity would be greater in this model. Starting at 8 weeks of age, the L-PGDS KO and C57BL/6 mice were maintained on a low-fat or high-fat diet. After 20 or 37 weeks, fasting metabolic parameters and basal HPA axis hormones were measured and compared between genotypes. Correlation analyses were performed to identify associations between obesity-related chronic metabolic changes and changes in the basal activity of the HPA axis. Our results have identified strong positive correlations between total cholesterol, LDL-cholesterol, glucose, and HPA axis hormones that increase with age in the C57BL/6 mice. These data confirm that obesity-related elevations in cholesterol and glucose can heighten basal HPA activity. Additionally, the L-PGDS KO mice show early elevations in HPA activity with no age-related changes relative to the C57BL/6 mice.
- Published
- 2013
- Full Text
- View/download PDF
31. Systemic and local ACTH produced during inflammatory states promotes osteochondrogenic mesenchymal cell differentiation contributing to the pathologic progression of calcified atherosclerosis.
- Author
-
Evans JF and Ragolia L
- Subjects
- Adrenocorticotropic Hormone biosynthesis, Chondrocytes pathology, Humans, Inflammation pathology, Models, Theoretical, Osteoblasts pathology, Pro-Opiomelanocortin physiology, Receptors, Melanocortin physiology, Adrenocorticotropic Hormone physiology, Atherosclerosis pathology, Calcinosis, Cell Differentiation physiology, Inflammation metabolism, Mesenchymal Stem Cells pathology
- Abstract
There are many well-known roles for the proopiomelanocortin (POMC) derived peptides and their receptors, the melanocortin receptors (MC-R). The focus here is on the evolving role of the melanocortin system in inflammation. Chronic inflammatory states such as those occurring in diabetes and obesity are associated with both a hyperactive hypothalamic-pituitary-adrenal (HPA) axis as well as increased incidence of atherosclerosis. An inflammation-induced hyperactive HPA axis along with increased leukocyte infiltration can lead to significant exposure to melanocortin peptides, particularly ACTH, in an inflamed vasculature. Mesenchymal progenitor cells are present throughout the vasculature, express receptors for the melanocortin peptides, and respond to ACTH with increased osteochondrogenic differentiation. Coupled to the increased exposure to ACTH during HPA hyperactivity is increased glucocorticoid (GC) exposure. GCs also promote chondrogenic differentiation of mesenchymal progenitors and increase their expression of MC-R as well as their expression of POMC and its cleavage products. It is hypothesized that during inflammatory states systemically produced ACTH and glucocorticoid as well as ACTH produced locally by macrophage and other immune cells, can influence and potentiate mesenchymal progenitor cell differentiation along the osteochondrogenic lineages. In turn the increase in osteochondrogenic matrix contributes to the pathophysiological progression of the calcified atherosclerotic plaque. The roles of the melanocortin system in inflammation and its resolution have just begun to be explored. Investigations into the ACTH-induced matrix changes among mesenchymal cell populations are warranted. ACTH signaling through the MC-R represents a new therapeutic target for the prevention and treatment of calcified atherosclerosis., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
32. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
- Author
-
Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, and Chopra R
- Subjects
- Adaptor Proteins, Signal Transducing, HEK293 Cells, Humans, Lenalidomide, Thalidomide pharmacology, Ubiquitin-Protein Ligases, Ubiquitination, Adjuvants, Immunologic pharmacology, Antineoplastic Agents pharmacology, Peptide Hydrolases drug effects, Thalidomide analogs & derivatives
- Abstract
Thalidomide and the immunomodulatory drug, lenalidomide, are therapeutically active in hematological malignancies. The ubiquitously expressed E3 ligase protein cereblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes. CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells. Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for lenalidomide resistance in H929 myeloma cell lines was accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable. Our biophysical, biochemical and gene silencing studies show that CRBN is a proximate, therapeutically important molecular target of lenalidomide and pomalidomide.
- Published
- 2012
- Full Text
- View/download PDF
33. Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2.
- Author
-
Bain G, King CD, Brittain J, Hartung JP, Dearmond I, Stearns B, Truong YP, Hutchinson JH, Evans JF, and Holme K
- Subjects
- Adolescent, Adult, Area Under Curve, Double-Blind Method, Eosinophils cytology, Eosinophils drug effects, Female, Humans, Male, Methylurea Compounds adverse effects, Methylurea Compounds pharmacokinetics, Middle Aged, Phenylacetates adverse effects, Phenylacetates pharmacokinetics, Prostaglandin D2 pharmacology, Receptors, Immunologic metabolism, Receptors, Prostaglandin metabolism, Young Adult, Methylurea Compounds administration & dosage, Phenylacetates administration & dosage, Receptors, Immunologic antagonists & inhibitors, Receptors, Prostaglandin antagonists & inhibitors
- Abstract
The prostaglandin D(2) receptor type 2 (DP2) and its ligand, PGD(2), have been implicated in the development of asthma and other inflammatory diseases. The authors evaluated the pharmacodynamics, pharmacokinetics and safety of [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid sodium salt (AM211), a novel and potent DP2 antagonist, in healthy participants. Single and multiple doses of AM211 demonstrated dose-dependent inhibition of eosinophil shape change in blood with near-complete inhibition observed at trough after dosing 200 mg once daily for 7 days. Maximum plasma concentrations and exposures of AM211 increased in a greater-than-dose-proportional manner after single and multiple dosing. After multiple dosing, the exposures on day 7 were higher than on day 1 with accumulation ratio values ranging from 1.4 to 1.5. Mean terminal half-life values ranged from 14 to 25 hours across the dose range of 100 to 600 mg. AM211 was well tolerated at all doses in both the single- and multiple-dose cohorts. These data support additional clinical studies to evaluate AM211 in asthma and other inflammatory diseases.
- Published
- 2012
- Full Text
- View/download PDF
34. Functional melanocortin-2 receptors are expressed by mouse aorta-derived mesenchymal progenitor cells.
- Author
-
Evans JF, Fernando A, and Ragolia L
- Subjects
- Adrenocorticotropic Hormone pharmacology, Animals, Aorta cytology, Aorta drug effects, Azo Compounds, Calcium metabolism, Cells, Cultured, Collagen genetics, Collagen metabolism, Extracellular Matrix drug effects, Fura-2, Gene Expression drug effects, Macrophages cytology, Macrophages drug effects, Macrophages metabolism, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells drug effects, Mice, Mice, Inbred C57BL, Pro-Opiomelanocortin genetics, Pro-Opiomelanocortin metabolism, Proprotein Convertase 1 genetics, Proprotein Convertase 1 metabolism, Rats, Rats, Inbred WKY, Receptor, Melanocortin, Type 2 genetics, Receptor, Melanocortin, Type 3 genetics, Signal Transduction drug effects, Aorta metabolism, Mesenchymal Stem Cells metabolism, Receptor, Melanocortin, Type 2 metabolism, Receptor, Melanocortin, Type 3 metabolism
- Abstract
A local melanocortin system is active during tissue injury and inflammation. Thus far this system has been described as autocrine in nature where local production of pro-opiomelanocortin (POMC) peptides by leukocytes feeds back on melanocortin receptor (MC-R) expressing immune cells to quell inflammatory cytokine production. Here we present evidence that POMC peptides may generate extracellular matrix (ECM) changes by inducing matrix production by cells of the mesenchymal lineage through activation of the MC2-R. Using immunoblot, we determined that mouse aorta-derived mesenchymal progenitor cells express both MC2-R and MC3-R. These progenitors respond to treatment with ACTH by increasing collagen matrix synthesis as assessed by picrosirius red stain and (3)H-proline incorporation. ACTH also induces transient increases in intracellular calcium ([Ca(2+)](i)) as assessed using the fluorescent Ca(2+) indicator, fura-2. The ACTH-induced changes in [Ca(2+)](i) are consistent with MC2-R signaling and consist of both an intracellular release and an extracellular influx of Ca(2+). Both mouse aortic mesenchymal progenitors and mouse macrophage cells express POMC and the prohormone convertase 1/3 (PC1/3) indicating they have the potential to contribute to the local production of POMC peptides. These data demonstrate functional MC2-R expression in mouse aorta-derived mesenchymal progenitors and implicate both macrophage and mesenchymal cells as relevant sources of local POMC peptides., (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
35. DP2 (CRTh2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virus.
- Author
-
Stebbins KJ, Broadhead AR, Musiyenko A, Barik S, Scott JM, Truong YP, Stearns BA, Hutchinson JH, Prasit P, Evans JF, and Lorrain DS
- Subjects
- Administration, Topical, Allergens immunology, Ambrosia immunology, Animals, Conjunctivitis, Allergic immunology, Conjunctivitis, Allergic metabolism, Conjunctivitis, Viral immunology, Conjunctivitis, Viral metabolism, Disease Models, Animal, Female, Guinea Pigs, Interleukin-4 immunology, Interleukin-4 metabolism, Male, Mice, Mice, Inbred BALB C, Ovalbumin immunology, Receptors, Immunologic immunology, Receptors, Prostaglandin immunology, Respiratory Syncytial Virus Infections immunology, Respiratory Syncytial Virus Infections metabolism, Anti-Allergic Agents therapeutic use, Benzylamines therapeutic use, Conjunctivitis, Allergic drug therapy, Conjunctivitis, Viral drug therapy, Receptors, Immunologic antagonists & inhibitors, Receptors, Prostaglandin antagonists & inhibitors, Respiratory Syncytial Virus Infections drug therapy
- Abstract
Background: Allergic conjunctivitis is characterized by itchy, watery and swollen eyes which occur in response to exposure to seasonal or environmental allergens. The early phase reaction of allergic conjunctivitis is primarily mediated by mast cell degranulation while the late phase reaction is driven by Th2 cells and eosinophils. Prostaglandin D(2) (PGD(2)), released from mast cells, is present in allergic conjunctival tears and may elicit classical allergic responses via interaction with the high-affinity DP2 receptor (chemoattractant receptor-homologous molecule expressed on Th2 cells, CRTh2). Furthermore, antagonism of this receptor is well known to inhibit eosinophil chemotaxis, basophil activation and Th2 cytokine production. PGD(2), therefore, may be involved in both early and late phase reactions in response to allergen challenge., Methods: Thus, we explored whether our novel and selective DP2 antagonist AM156 would be efficacious in animal models of allergic conjunctivitis. Furthermore, as respiratory syncytial virus (RSV) has been implicated in the pathogenesis of allergic conjunctivitis, we examined the effects of DP2 antagonism in a murine model of RSV ocular infection., Results: Utilizing a guinea pig ovalbumin model and a murine ragweed model we demonstrated that AM156 reduces redness, discharge and swelling in response to allergen challenge. These effects were equal to or greater than those of current clinical treatment options for allergic conjunctivitis including topical corticosteroids and a dual-mechanism antihistamine and decongestant. AM156 significantly reduced RSV-induced ocular inflammation and IL-4 production., Conclusion: These results suggest that a topical DP2 antagonist such as AM156 may represent a novel therapeutic for allergic conjunctivitis., (Copyright © 2011 S. Karger AG, Basel.)
- Published
- 2012
- Full Text
- View/download PDF
36. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.
- Author
-
Stock NS, Bain G, Zunic J, Li Y, Ziff J, Roppe J, Santini A, Darlington J, Prodanovich P, King CD, Baccei C, Lee C, Rong H, Chapman C, Broadhead A, Lorrain D, Correa L, Hutchinson JH, Evans JF, and Prasit P
- Subjects
- 5-Lipoxygenase-Activating Protein Inhibitors pharmacokinetics, 5-Lipoxygenase-Activating Protein Inhibitors pharmacology, Administration, Oral, Animals, Anti-Asthmatic Agents pharmacokinetics, Anti-Asthmatic Agents pharmacology, Bronchoalveolar Lavage, Cytochrome P-450 Enzyme Inhibitors, Dogs, Female, Humans, In Vitro Techniques, Indoles pharmacokinetics, Indoles pharmacology, Male, Pentanoic Acids pharmacokinetics, Pentanoic Acids pharmacology, Rats, Rats, Sprague-Dawley, Structure-Activity Relationship, 5-Lipoxygenase-Activating Protein Inhibitors chemical synthesis, Anti-Asthmatic Agents chemical synthesis, Indoles chemical synthesis, Pentanoic Acids chemical synthesis
- Abstract
The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc is described (AM803, now GSK2190915). Building upon AM103 (1) (Hutchinson et al. J. Med Chem.2009, 52, 5803-5815; Stock et al. Bioorg. Med. Chem. Lett. 2010, 20, 213-217; Stock et al. Bioorg. Med. Chem. Lett.2010, 20, 4598-4601), SAR studies centering around the pyridine moiety led to the discovery of compounds that exhibit significantly increased potency in a human whole blood assay measuring LTB(4) inhibition with longer drug preincubation times (15 min vs 5 h). Further studies identified 11cc with a potency of 2.9 nM in FLAP binding, an IC(50) of 76 nM for inhibition of LTB(4) in human blood (5 h incubation) and excellent preclinical toxicology and pharmacokinetics in rat and dog. 11cc also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. This compound has successfully completed phase 1 clinical studies in healthy volunteers and is currently undergoing phase 2 trials in asthmatic patients.
- Published
- 2011
- Full Text
- View/download PDF
37. Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.
- Author
-
Scott JM, Baccei C, Bain G, Broadhead A, Evans JF, Fagan P, Hutchinson JH, King C, Lorrain DS, Lee C, Prasit P, Prodanovich P, Santini A, and Stearns BA
- Subjects
- Animals, Biological Availability, Dogs, Mice, Phenylacetates chemistry, Phenylacetates pharmacokinetics, Phenylacetates therapeutic use, Rats, Disease Models, Animal, Drug Discovery, Phenylacetates pharmacology, Receptors, Immunologic antagonists & inhibitors, Receptors, Prostaglandin antagonists & inhibitors, Rhinitis, Allergic, Perennial drug therapy
- Abstract
Biphenylacetic acid (5) was identified through a library screen as an inhibitor of the prostaglandin D(2) receptor DP2 (CRTH2). Optimization for potency and pharmacokinetic properties led to a series of selective CRTH2 antagonists. Compounds demonstrated potency in a human DP2 binding assay and a human whole blood eosinophil shape change assay, as well as good oral bioavailability in rat and dog, and efficacy in a mouse model of allergic rhinitis following oral dosing., (Copyright © 2011. Published by Elsevier Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
38. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions.
- Author
-
Bäck M, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, and Rovati GE
- Subjects
- Animals, Cysteine agonists, Cysteine antagonists & inhibitors, Cysteine metabolism, Humans, International Agencies, Leukotriene Antagonists therapeutic use, Leukotrienes agonists, Leukotrienes metabolism, Molecular Targeted Therapy, Organ Specificity, Receptors, Leukotriene chemistry, Receptors, Leukotriene genetics, Receptors, Leukotriene metabolism, Signal Transduction drug effects, Terminology as Topic, Gene Expression Regulation, Receptors, Leukotriene classification
- Abstract
The seven-transmembrane G protein-coupled receptors activated by leukotrienes are divided into two subclasses based on their ligand specificity for either leukotriene B(4) or the cysteinyl leukotrienes (LTC(4), LTD(4), and LTE(4)). These receptors have been designated BLT and CysLT receptors, respectively, and a subdivision into BLT(1) and BLT(2) receptors and CysLT(1) and CysLT(2) receptors has been established. However, recent findings have also indicated the existence of putative additional leukotriene receptor subtypes. Furthermore, other ligands interact with the leukotriene receptors. Finally, leukotrienes may also activate other receptor classes, such as purinergic receptors. The aim of this review is to provide an update on the pharmacology, expression patterns, and pathophysiological roles of the leukotriene receptors as well as the therapeutic developments in this area of research.
- Published
- 2011
- Full Text
- View/download PDF
39. Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation.
- Author
-
Bain G, Lorrain DS, Stebbins KJ, Broadhead AR, Santini AM, Prodanovich P, Darlington J, King CD, Lee C, Baccei C, Stearns B, Troung Y, Hutchinson JH, Prasit P, and Evans JF
- Subjects
- Adult, Animals, Dogs, Female, Guinea Pigs, HEK293 Cells, Humans, Hypersensitivity drug therapy, Hypersensitivity immunology, Hypersensitivity metabolism, Male, Methylurea Compounds chemistry, Methylurea Compounds pharmacology, Mice, Mice, Inbred BALB C, Phenylacetates chemistry, Phenylacetates pharmacology, Pneumonia drug therapy, Pneumonia immunology, Pneumonia metabolism, Prostaglandin Antagonists chemistry, Prostaglandin Antagonists pharmacology, Protein Binding physiology, Random Allocation, Rats, Rats, Sprague-Dawley, Receptors, Immunologic immunology, Receptors, Immunologic metabolism, Receptors, Prostaglandin immunology, Receptors, Prostaglandin metabolism, Rhinitis, Allergic, Perennial immunology, Rhinitis, Allergic, Perennial metabolism, Disease Models, Animal, Methylurea Compounds therapeutic use, Phenylacetates therapeutic use, Prostaglandin Antagonists therapeutic use, Receptors, Immunologic antagonists & inhibitors, Receptors, Prostaglandin antagonists & inhibitors, Rhinitis, Allergic, Perennial drug therapy
- Abstract
The prostaglandin D(2) (PGD(2)) receptor type 2 (DP2) is a G protein-coupled receptor that has been shown to be involved in a variety of allergic diseases, including allergic rhinitis, asthma, and atopic dermatitis. In this study, we describe the preclinical pharmacological and pharmacokinetic properties of the small-molecule DP2 antagonist [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid (AM211). We determine that AM211 has high affinity for human, mouse, rat, and guinea pig DP2 and it shows selectivity over other prostanoid receptors and enzymes. Antagonist activity of AM211 at the DP2 receptor was confirmed by inhibition of PGD(2)-stimulated guanosine 5'-O-[γ-thio]triphosphate binding to membranes expressing human DP2. A basophil activation assay and a whole-blood assay of eosinophil shape change were used to demonstrate the ability of AM211 to potently antagonize PGD(2)-stimulated functional responses in relevant human cells and in the context of a physiologically relevant environment. AM211 exhibits good oral bioavailability in rats and dogs and dose-dependently inhibits 13,14-dihydro-15-keto-PGD(2)-induced leukocytosis in a guinea pig pharmacodynamic assay. AM211 demonstrates efficacy in two animal models of allergic inflammation, including an ovalbumin-induced lung inflammation model in guinea pigs and an ovalbumin-induced mouse model of allergic rhinitis. AM211 represents a potent and selective antagonist of DP2 that may be used clinically to evaluate the role of DP2 in T helper 2-driven allergic inflammatory diseases.
- Published
- 2011
- Full Text
- View/download PDF
40. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.
- Author
-
Swaney JS, Chapman C, Correa LD, Stebbins KJ, Broadhead AR, Bain G, Santini AM, Darlington J, King CD, Baccei CS, Lee C, Parr TA, Roppe JR, Seiders TJ, Ziff J, Prasit P, Hutchinson JH, Evans JF, and Lorrain DS
- Subjects
- Administration, Oral, Animals, Antifibrinolytic Agents chemistry, CHO Cells, Cell Line, Tumor, Cricetinae, Cricetulus, Dogs, Humans, Male, Mice, Protein Binding physiology, Rats, Rats, Sprague-Dawley, Receptors, Lysophosphatidic Acid metabolism, Antifibrinolytic Agents administration & dosage, Antifibrinolytic Agents pharmacokinetics, Receptors, Lysophosphatidic Acid antagonists & inhibitors
- Abstract
Lysophosphatidic acid (LPA) is a bioactive phospholipid that signals through a family of at least six G protein-coupled receptors designated LPA₁₋₆. LPA type 1 receptor (LPA₁) exhibits widespread tissue distribution and regulates a variety of physiological and pathological cellular functions. Here, we evaluated the in vitro pharmacology, pharmacokinetic, and pharmacodynamic properties of the LPA₁-selective antagonist AM095 (sodium, {4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetate) and assessed the effects of AM095 in rodent models of lung and kidney fibrosis and dermal wound healing. In vitro, AM095 was a potent LPA₁ receptor antagonist because it inhibited GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA₁ with IC₅₀ values of 0.98 and 0.73 μM, respectively, and exhibited no LPA₁ agonism. In functional assays, AM095 inhibited LPA-driven chemotaxis of CHO cells overexpressing mouse LPA₁ (IC₅₀= 778 nM) and human A2058 melanoma cells (IC₅₀ = 233 nM). In vivo, we demonstrated that AM095: 1) had high oral bioavailability and a moderate half-life and was well tolerated at the doses tested in rats and dogs after oral and intravenous dosing, 2) dose-dependently reduced LPA-stimulated histamine release, 3) attenuated bleomycin-induced increases in collagen, protein, and inflammatory cell infiltration in bronchalveolar lavage fluid, and 4) decreased kidney fibrosis in a mouse unilateral ureteral obstruction model. Despite its antifibrotic activity, AM095 had no effect on normal wound healing after incisional and excisional wounding in rats. These data demonstrate that AM095 is an LPA₁ receptor antagonist with good oral exposure and antifibrotic activity in rodent models.
- Published
- 2011
- Full Text
- View/download PDF
41. Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.
- Author
-
Stock N, Volkots D, Stebbins K, Broadhead A, Stearns B, Roppe J, Parr T, Baccei C, Bain G, Chapman C, Correa L, Darlington J, King C, Lee C, Lorrain DS, Prodanovich P, Santini A, Evans JF, Hutchinson JH, and Prasit P
- Subjects
- Administration, Oral, Animals, Disease Models, Animal, Dogs, Eosinophils drug effects, Eosinophils immunology, Humans, Inflammation drug therapy, Mice, Phenylacetates pharmacokinetics, Phenylacetates therapeutic use, Pyridines pharmacokinetics, Pyridines therapeutic use, Receptors, Immunologic metabolism, Receptors, Prostaglandin metabolism, Phenylacetates chemistry, Pyridines chemistry, Receptors, Immunologic antagonists & inhibitors, Receptors, Prostaglandin antagonists & inhibitors
- Abstract
Compound 21 (AM432) was identified as a potent and selective antagonist of the DP(2) receptor (CRTH2). Modification of a bi-aryl core identified a series of tri-aryl antagonists of which compound 21 proved a viable clinical candidate. AM432 shows excellent potency in a human whole blood eosinophil shape change assay with prolonged incubation, a comparatively long off-rate from the DP(2) receptor, excellent pharmacokinetics in dog and in vivo activity in two mouse models of inflammatory disease after oral dosing., (Copyright © 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
42. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation.
- Author
-
Lorrain DS, Bain G, Correa LD, Chapman C, Broadhead AR, Santini AM, Prodanovich PP, Darlington JV, Stock NS, Zunic J, King CD, Lee C, Baccei CS, Stearns B, Roppe J, Hutchinson JH, Prasit P, and Evans JF
- Subjects
- 5-Lipoxygenase-Activating Proteins, Animals, Chronic Disease, Cysteine biosynthesis, Disease Models, Animal, Female, Humans, Indoles pharmacokinetics, Indoles therapeutic use, Inflammation drug therapy, Leukotriene B4 biosynthesis, Leukotrienes biosynthesis, Lung drug effects, Lung metabolism, Male, Mice, Pentanoic Acids pharmacokinetics, Pentanoic Acids therapeutic use, Platelet Activating Factor pharmacology, Propionates pharmacokinetics, Propionates therapeutic use, Rats, Substrate Specificity, Zymosan pharmacology, Carrier Proteins antagonists & inhibitors, Indoles pharmacology, Inflammation metabolism, Membrane Proteins antagonists & inhibitors, Pentanoic Acids pharmacology, Propionates pharmacology
- Abstract
We evaluated the in vivo pharmacological properties of AM803 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, a selective five-lipoxygenase-activating protein (FLAP) inhibitor, using rat and mouse models of acute inflammation. Oral administration of AM803 (1 mg/kg) resulted in sustained inhibition of ex vivo ionophore-challenged whole blood LTB4 biosynthesis with >90% inhibition for up to 12 h and an EC50 of approximately 7 nM. When rat lungs were challenged in vivo with calcium-ionophore, AM803 inhibited LTB4 and cysteinyl leukotriene (CysLT) production with ED50s of 0.12 mg/kg and 0.37 mg/kg, respectively. The inhibition measured 16 h following a single oral dose of 3 mg/kg was 86% and 41% for LTB4 and CysLTs, respectively. In an acute inflammation setting, AM803 dose-dependently reduced LTB4, CysLTs, plasma protein extravasation and neutrophil influx induced by peritoneal zymosan injection. Finally, AM803 increased survival time in mice exposed to a lethal intravenous injection of platelet activating factor (PAF). The magnitude of effect was similar to that of an inhibitor of five-lipoxygenase (5-LO) and LTA4 hydrolase but superior to a leukotriene CysLT1 receptor antagonist. In summary, AM803 is a novel, potent and selective FLAP inhibitor that has excellent pharmacodynamic properties in vivo and is effective in animal models of acute inflammation and in a model of lethal shock., (Copyright (c) 2010 Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
43. Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis.
- Author
-
Terasaki Y, Yahiro K, Pacheco-Rodriguez G, Steagall WK, Stylianou MP, Evans JF, Walker AM, and Moss J
- Subjects
- Animals, Blotting, Western methods, Cell Proliferation, Female, Forced Expiratory Volume, Humans, Lung Diseases complications, Lymphangioleiomyomatosis complications, Lymphangioleiomyomatosis pathology, Muscle, Smooth metabolism, Muscle, Smooth pathology, Pneumothorax complications, Pneumothorax metabolism, Rats, Rats, Inbred Strains, Reverse Transcriptase Polymerase Chain Reaction methods, Signal Transduction, Tuberous Sclerosis Complex 2 Protein, Tumor Cells, Cultured, Lung Diseases blood, Lymphangioleiomyomatosis blood, Prolactin blood, Tumor Suppressor Proteins blood
- Abstract
Rationale: Lymphangioleiomyomatosis, a cystic lung disease of women, is characterized by proliferation of smooth muscle-like lymphangioleiomyomatosis cells, which possess mutations in the tuberous sclerosis complex genes, TSC1/TSC2. Growth factors involved in lymphangioleiomyomatosis cell proliferation are unknown. Prolactin, an important reproductive hormone in women, is known to promote cell proliferation and survival in other tissues., Objectives: To determine the role of prolactin in signaling and proliferation in lymphangioleiomyomatosis., Methods: Prolactin levels in the sera of patients with lymphangioleiomyomatosis were correlated with clinical status. Components of prolactin signal transduction pathways were assessed in lymphangioleiomyomatosis lesions from human lung explants by real-time reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. Prolactin effects on proliferation and signaling were quantified in tuberin-deficient and tuberin-expressing rat cells in vitro., Measurements and Main Results: Higher prolactin levels in the sera of patients with lymphangioleiomyomatosis were associated with a faster rate of decline in FEV(1) and an increased history of pneumothorax (P < 0.01). Higher levels of prolactin and prolactin receptor mRNA and immunoreactivity were found in lymphangioleiomyomatosis lesions when compared with vascular smooth muscle cells in the same region of tissue. This was accompanied by evidence of activation of signal transducer and activator of transcription-1 (STAT1), STAT3, p44/42, and p38 mitogen-activated protein kinase. Tsc2(-/-) Eker rat embryonic fibroblasts expressed more prolactin receptor than did Tsc2(+/+) cells, and responded to prolactin with increased proliferation and activation of the same signaling pathways seen in vivo., Conclusions: Prolactin may be an important growth factor in the pathogenesis of lymphangioleiomyomatosis.
- Published
- 2010
- Full Text
- View/download PDF
44. 5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.
- Author
-
Stock N, Baccei C, Bain G, Chapman C, Correa L, Darlington J, King C, Lee C, Lorrain DS, Prodanovich P, Santini A, Schaab K, Evans JF, Hutchinson JH, and Prasit P
- Subjects
- 5-Lipoxygenase-Activating Proteins metabolism, Administration, Topical, Animals, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors therapeutic use, Humans, Indoles chemistry, Indoles therapeutic use, Leukotrienes biosynthesis, Mice, Propionates chemistry, Propionates therapeutic use, Rats, Skin Diseases chemically induced, Skin Diseases drug therapy, Enzyme Inhibitors chemistry, Indoles chemical synthesis, Propionates chemical synthesis
- Abstract
AM643 (compound 6, 3-{3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid) was identified as a potential candidate for formulation as a topical agent for the treatment of skin disorders involving leukotriene production. Dermal application of 6 using a prototypical vehicle in a murine ear arachidonic acid model showed significant reduction in the concentrations of leukotrienes in mouse skin with concomitant reduction in ear swelling., (Copyright 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
45. Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation.
- Author
-
Stebbins KJ, Broadhead AR, Correa LD, Scott JM, Truong YP, Stearns BA, Hutchinson JH, Prasit P, Evans JF, and Lorrain DS
- Subjects
- Animals, Anti-Allergic Agents pharmacology, Benzylamines pharmacology, Bronchoalveolar Lavage Fluid cytology, Bronchoalveolar Lavage Fluid immunology, Cytokines metabolism, Disease Models, Animal, Female, Immunoglobulin E blood, Lung immunology, Metaplasia immunology, Mice, Mice, Inbred BALB C, Mucins metabolism, Pneumonia immunology, Pneumonia metabolism, Rhinitis, Allergic, Perennial metabolism, Anti-Allergic Agents therapeutic use, Asthma drug therapy, Benzylamines therapeutic use, Lung pathology, Pneumonia drug therapy, Pyroglyphidae immunology, Receptors, Immunologic antagonists & inhibitors, Receptors, Prostaglandin antagonists & inhibitors, Rhinitis, Allergic, Perennial drug therapy
- Abstract
Prostaglandin D(2) (PGD(2)) is derived from arachidonic acid and binds with high affinity to the G protein coupled receptors prostanoid DP(1) and DP(2). Interaction with DP(2) results in cell chemotaxis, eosinophil degranulation, eosinophil shape change, adhesion molecule upregulation and Th2 cytokine production. In allergic rhinitis and allergic asthma PGD(2) is released from mast cells in response to allergen challenge and may trigger symptoms such as sneezing, rhinorrhea, pruritus, mucus hypersecretion and pulmonary inflammation. In Japan, ramatroban, a dual prostanoid DP(2)/prostanoid TP receptor antagonist, is marketed for allergic rhinitis while selective DP(2) antagonists are currently under investigation as therapeutics for asthma and allergic rhinitis. In the studies described herein, we investigated the efficacy of AM156, a novel selective prostanoid DP(2) receptor antagonist, in murine models of allergic rhinitis and asthma. AM156 inhibited sneezing and nasal rubs in a model of allergic rhinitis. AM156 inhibited pulmonary inflammation and mucus hypersecretion induced by chronic inhalation of house dust mite. These results suggest that selective prostanoid DP(2) receptor antagonists such as AM156 may provide beneficial effects for the clinical treatment of diseases such as allergic rhinitis and asthma., ((c) 2010 Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
46. Seeing the future of bioactive lipid drug targets.
- Author
-
Evans JF and Hutchinson JH
- Subjects
- Genome, Human, Humans, Hypolipidemic Agents chemistry, Molecular Structure, Signal Transduction, Structure-Activity Relationship, Drug Design, Hypolipidemic Agents pharmacology, Lipid Metabolism drug effects
- Published
- 2010
- Full Text
- View/download PDF
47. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP).
- Author
-
Bain G, King CD, Rewolinski M, Schaab K, Santini AM, Shapiro D, Moran M, van de Wetering de Rooij S, Roffel AF, Schuilenga-Hut P, Milne GL, Lorrain DS, Li Y, Arruda JM, Hutchinson JH, Prasit P, and Evans JF
- Subjects
- 5-Lipoxygenase-Activating Proteins, Adolescent, Adult, Aged, Area Under Curve, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Indoles adverse effects, Indoles pharmacokinetics, Male, Middle Aged, Propionates adverse effects, Propionates pharmacokinetics, Young Adult, Carrier Proteins antagonists & inhibitors, Indoles pharmacology, Leukotriene B4 biosynthesis, Leukotriene E4 urine, Membrane Proteins antagonists & inhibitors, Propionates pharmacology
- Abstract
The 5-lipoxygenase-activating protein (FLAP) gene and an increase in leukotriene (LT) production are linked to the risk of asthma, myocardial infarction, and stroke. We evaluated the pharmacodynamics, pharmacokinetics, and tolerability of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel FLAP inhibitor, in healthy subjects. Single and multiple doses of AM103 demonstrated dose-dependent inhibition of blood LTB(4) production and dose-related inhibition of urinary LTE(4). After a single oral dose (50-1,000 mg) of AM103, the maximum concentration (C(max)) and area under the curve (AUC) in plasma increased in a dose-dependent manner. After multiple-dose administration (50-1,000 mg once daily for 11 days), there were no significant differences in the pharmacokinetic parameters between the first and last days of treatment. AM103 was well tolerated at all doses in both the single- and multiple-dose cohorts. Further clinical trials with AM103 in inflammatory diseases are warranted.
- Published
- 2010
- Full Text
- View/download PDF
48. Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung.
- Author
-
Stebbins KJ, Broadhead AR, Baccei CS, Scott JM, Truong YP, Coate H, Stock NS, Santini AM, Fagan P, Prodanovich P, Bain G, Stearns BA, King CD, Hutchinson JH, Prasit P, Evans JF, and Lorrain DS
- Subjects
- Animals, Benzylamines pharmacokinetics, Benzylamines pharmacology, Cell Line, Cell Movement, Female, Guinea Pigs, Humans, In Vitro Techniques, Inflammation immunology, Inflammation metabolism, Inflammation prevention & control, Lung immunology, Lung pathology, Lymphocytes drug effects, Lymphocytes immunology, Male, Metaplasia, Mice, Mice, Inbred BALB C, Neutrophils drug effects, Neutrophils immunology, Niacin analogs & derivatives, Niacin pharmacokinetics, Niacin pharmacology, Pulmonary Disease, Chronic Obstructive etiology, Pulmonary Disease, Chronic Obstructive immunology, Pulmonary Disease, Chronic Obstructive pathology, Respiratory Mucosa pathology, Lung drug effects, Mucus metabolism, Pulmonary Disease, Chronic Obstructive prevention & control, Receptors, Immunologic antagonists & inhibitors, Receptors, Prostaglandin antagonists & inhibitors, Respiratory Mucosa drug effects, Smoking adverse effects
- Abstract
Prostaglandin D(2) (PGD(2)) is one of a family of biologically active lipids derived from arachidonic acid via the action of COX-1 and COX-2. PGD(2) is released from mast cells and binds primarily to two G protein-coupled receptors, namely DP1 and DP2, the latter also known as chemoattractant receptor-homologous molecule expressed on Th2 cells. DP2 is predominantly expressed on eosinophils, Th2 cells, and basophils, but it is also expressed to a lesser extent on monocytes, mast cells, and epithelial cells. Interaction of PGD(2) and its active metabolites with DP2 results in cellular chemotaxis, degranulation, up-regulation of adhesion molecules, and cytokine production. Chronic obstructive pulmonary disease (COPD) is a chronic progressive inflammatory disease characterized by elevated lung neutrophils, macrophages, and CD8+ T lymphocytes and mucus hypersecretion. Cigarette smoke contributes to the etiology of COPD and was used here as a provoking agent in a murine model of COPD. In an acute model, {2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-6-methoxy-4'-trifluoro-methyl-biphenyl-3-yl}-acetic acid, sodium salt (AM156) and (5-{2-[(benzoyloxycarbonyl-ethyl-amino)-methyl]-4-trifluoromethyl-phenyl}-pyridin-3-yl)-acetic acid, sodium salt) (AM206), potent DP2 receptor antagonists, dose-dependently inhibited influx of neutrophils and lymphocytes to smoke-exposed airways. In a subchronic model, AM156 and AM206 inhibited neutrophil and lymphocyte trafficking to the airways. Furthermore, AM156 and AM206 treatment inhibited mucus cell metaplasia and prevented the thickening of the airway epithelial layer induced by cigarette smoke. These data suggest that DP2 receptor antagonism may represent a novel therapy for COPD or other conditions characterized by neutrophil influx, mucus hypersecretion, and airway remodeling.
- Published
- 2010
- Full Text
- View/download PDF
49. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.
- Author
-
Stock N, Baccei C, Bain G, Broadhead A, Chapman C, Darlington J, King C, Lee C, Li Y, Lorrain DS, Prodanovich P, Rong H, Santini A, Zunic J, Evans JF, Hutchinson JH, and Prasit P
- Subjects
- 5-Lipoxygenase-Activating Proteins, Animals, Carrier Proteins metabolism, Humans, Indoles chemical synthesis, Indoles pharmacology, Leukotrienes blood, Leukotrienes metabolism, Lipoxygenase Inhibitors chemical synthesis, Lipoxygenase Inhibitors pharmacology, Membrane Proteins metabolism, Mice, Models, Animal, Pentanoic Acids chemical synthesis, Pentanoic Acids pharmacology, Rats, Structure-Activity Relationship, Carrier Proteins antagonists & inhibitors, Indoles chemistry, Lipoxygenase Inhibitors chemistry, Membrane Proteins antagonists & inhibitors, Pentanoic Acids chemistry
- Abstract
A series of potent 5-lipoxygenase-activating protein (FLAP) inhibitors are herein described. SAR studies focused on the discovery of novel alicyclic moieties appended to an indole core to optimize potency, physical properties and off-target activities. Subsequent SAR on the N-benzyl substituent of the indole led to the discovery of compound 39 (AM679) which showed potent inhibition of leukotrienes in human blood and in a rodent bronchoalvelolar lavage (BAL) challenge model., (Copyright 2009 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
50. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
- Author
-
Lorrain DS, Bain G, Correa LD, Chapman C, Broadhead AR, Santini AM, Prodanovich P, Darlington JV, Hutchinson JH, King C, Lee C, Baccei C, Li Y, Arruda JM, and Evans JF
- Subjects
- 5-Lipoxygenase-Activating Proteins, Acute Disease, Administration, Oral, Animals, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Asthma drug therapy, Asthma enzymology, Asthma metabolism, Chronic Disease, Disease Models, Animal, Dose-Response Relationship, Drug, Extravasation of Diagnostic and Therapeutic Materials drug therapy, Extravasation of Diagnostic and Therapeutic Materials enzymology, Extravasation of Diagnostic and Therapeutic Materials metabolism, Female, Humans, Indoles therapeutic use, Inflammation enzymology, Inflammation metabolism, Leukotriene B4 biosynthesis, Leukotriene B4 blood, Male, Mice, Mice, Inbred BALB C, Pneumonia drug therapy, Pneumonia enzymology, Pneumonia metabolism, Propionates therapeutic use, Rats, Rats, Sprague-Dawley, Zymosan, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Carrier Proteins antagonists & inhibitors, Indoles pharmacology, Inflammation drug therapy, Membrane Proteins antagonists & inhibitors, Propionates pharmacology
- Abstract
Leukotrienes (LTs) are proinflammatory lipid mediators synthesized by the conversion of arachidonic acid (AA) to LTA(4) by the enzyme 5-lipoxygenase (5-LO) in the presence of 5-LO-activating protein (FLAP). 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103) is a novel selective FLAP inhibitor in development for the treatment of respiratory conditions such as asthma. In a rat ex vivo whole-blood calcium ionophore-induced LTB(4) assay, AM103 (administered orally at 1 mg/kg) displayed >50% inhibition for up to 6 h with a calculated EC(50) of approximately 60 nM. When rat lung was challenged in vivo with calcium ionophore, AM103 inhibited LTB(4) and cysteinyl leukotriene (CysLT) production with ED(50) values of 0.8 and 1 mg/kg, respectively. In this model, the EC(50) derived from plasma AM103 was approximately 330 nM for inhibition of both LTB(4) and CysLT. In an acute inflammation setting, AM103 displayed dose-dependent inhibition of LTB(4), CysLT, and plasma protein extravasation induced by peritoneal zymosan injection. In a model of chronic lung inflammation using ovalbumin-primed and challenged BALB/c mice, AM103 reduced the concentrations of eosinophil peroxidase, CysLTs, and interleukin-5 in the bronchoalveolar lavage fluid. Finally, AM103 increased survival time in mice exposed to a lethal intravenous injection of platelet-activating factor. In summary, AM103 is a novel, potent and selective FLAP inhibitor that has excellent pharmacodynamic properties in vivo and is effective in animal models of acute and chronic inflammation and in a model of lethal shock.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.